Completed PHASE3 NCT01438775

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart

Sponsor: Nymox Corporation

Conditions Benign Prostatic Hyperplasia

Interventions NX-1207

Updated 8 times since 2017 Last updated: Apr 1, 2014 Started: Sep 30, 2011 Primary completion: Jan 31, 2013 Completion: Jan 31, 2013

Listed as NCT01438775, this PHASE3 trial focuses on Benign Prostatic Hyperplasia and remains completed. Sponsored by Nymox Corporation, it has been updated 8 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nymox Corporation

Data source: Nymox Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Annapolis, United States , Arlington, United States , Atherton, United States , Bismarck, United States , Brooklyn, United States , Concord, United States , Denver, United States , Englewood, United States , Forest Hill, United States and 18 more locations